Barclays’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Barclays’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13	Closed	–	–	6736
2019 Q4	$0	Sell	13 -84	-87%	-$204	﹤0.01%	7123
2019 Q3	$0	Sell	97 -7,661	-99%	-$27.6K	﹤0.01%	7399
2019 Q2	$51K	Buy	7,758 +5,627	+264%	+$21.4K	﹤0.01%	6086
2019 Q1	$8K	Buy	2,131 +1,831	+610%	+$9.94K	﹤0.01%	6632
2018 Q4	$1K	Sell	300 -3,002	-91%	-$38.4K	﹤0.01%	6871
2018 Q3	$64K	Buy	3,302 +2,086	+172%	+$52.7K	﹤0.01%	5919
2018 Q2	$39K	Sell	1,216 -826	-40%	-$29.7K	﹤0.01%	5802
2018 Q1	$74K	Sell	2,042 -4,260	-68%	-$280K	﹤0.01%	5608
2017 Q4	$498K	Buy	+6,302	New	+$466K	﹤0.01%	3835

Barclays's MLNT Position: Q1 2020 in Review

Barclays sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 13 shares.

Barclays first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $498K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Barclays reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Barclays sold 13 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
Barclays first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Barclays's Melinta Therapeutics, Inc. Common Stock position peaked at $498K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.